We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Ultrasensitive Droplet Biosensing Method Dramatically Shortens Identification Time for COVID-19

By LabMedica International staff writers
Posted on 30 Jul 2020
Scientists at Virginia Tech (Blacksburg, VA) have developed an ultrasensitive biosensing method that could dramatically shorten the amount of time required to verify the presence of the COVID-19 virus in a sample.

Currently, there is significant room to improve the pace of coronavirus testing. More...
COVID-19 verification tests require a few hours to complete, as verification of the presence of the virus requires the extraction and comparison of viral genetic material, a time-intensive process requiring a series of steps. The amount of virus in a sampling is also subject to error, and patients who have had the virus for a shorter period of time may test negative because there is not enough of the virus present to trigger a positive result.

The Virginia Tech scientists have developed a method in which all the contents of a sampling droplet can be detected, and there is no extraction or other tedious procedures. The contents of a microdroplet are condensed and characterized in minutes, drastically reducing the error margin and giving a clear picture of the materials present. The key to this method is in creating a surface over which water containing the sample travels in different ways. On surfaces where drops of water may “stick” or “glide,” the determining factor is friction. Surfaces that introduce more friction cause water droplets to stop, whereas less friction causes water droplets to glide over the surface uninhibited.

The method starts by placing a collected sample into liquid. The liquid is then introduced into an engineered substrate surface with both high and low friction regions. Droplets containing sample will move more quickly in some areas but anchor in other locations thanks to a nanoantenna coating that introduces more friction. These stop-and-go waterslides allow water droplets to be directed and transported in a programmable and reconfigurable fashion. The “stopped” locations are very small because of an intricately placed coating of carbon nanotubes on etched micropillars.

These prescribed spots with nanoantennae are established as active sensors. The substrate surface is then heated so that the anchored water droplet starts to evaporate. In comparison with natural evaporation, this so-called partial Leidenfrost-assisted evaporation provides a levitating force which causes the contents of the droplet to float toward the nanoantenna as the liquid evaporates. The bundle of sample particles shrinks toward the constrained center of the droplet base, resulting in a rapidly-produced package of analyte molecules. For fast sensing and analysis of these molecules, a laser beam is directed onto the spot with the packed-in molecules to generate their vibrational fingerprint light signals, a description of the molecules expressed in waveforms. All of this happens in just a few minutes, and the fingerprint spectrum and frequency of the coronavirus can be quickly picked out of a lineup of the returned data. The Virginia Tech scientists are now pursuing a patent on the method, and are also pursuing funding from the National Institutes for Health to deliver the method for widespread use.

Related Links:
Virginia Tech


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.